Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOMARIN PHARMACEUTICAL INC Director's Dealing 2015

Feb 10, 2015

30583_dirs_2015-02-10_e7538ca1-9279-4bbc-ba1e-fbbbc364267a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2013-03-18

Reporting Person: SPIEGELMAN DANIEL K (EVP, Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2013-03-18 Common Stock A 7 $61.4829 Acquired 68683 Direct
2013-03-18 Common Stock A 7 $61.3814 Acquired 68690 Direct
2013-03-20 Common Stock A 5 $61.9880 Acquired 68695 Direct
2013-03-20 Common Stock A 4 $61.4325 Acquired 68699 Direct
2013-06-19 Common Stock A 9 $58.5678 Acquired 68708 Direct
2013-06-19 Common Stock A 9 $58.8478 Acquired 68717 Direct
2013-09-10 Common Stock A 8 $70.0583 Acquired 68725 Direct
2013-09-10 Common Stock A 7 $70.3029 Acquired 68732 Direct
2013-10-04 Common Stock A 5 $74.0740 Acquired 68737 Direct
2013-10-07 Common Stock A 6 $74.8383 Acquired 68743 Direct
2013-10-30 Common Stock A 4 $66.4750 Acquired 68747 Direct
2013-10-30 Common Stock A 5 $65.7500 Acquired 68752 Direct
2013-11-20 Common Stock A 8 $65.8863 Acquired 68760 Direct
2014-03-05 Common Stock S 12 $82.9258 Disposed 68748 Direct
2014-05-02 Common Stock S 3 $58.0233 Disposed 68745 Direct
2014-05-02 Common Stock S 8 $58.7800 Disposed 68737 Direct
2014-08-06 Common Stock A 7 $62.1671 Acquired 68744 Direct
2014-08-06 Common Stock A 7 $62.1771 Acquired 68751 Direct
2014-09-03 Common Stock S 9 $69.8289 Disposed 68742 Direct
2014-09-03 Common Stock S 9 $69.7011 Disposed 68733 Direct

Footnotes

F1: Inadvertent transaction not directed by the reporting person through a broker-administered investment pool.

F2: Some of the transactions executed as reported herein resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"). The Reporting Person has made arrangements with the Issuer to disgorge short swing profits realized to the Issuer, and upon settlement, the Reporting Person will have discharged in full any obligation under Section 16(b) with respect to the reported transactions.